Bictegravir


Bictegravir is an antiviral drug of the integrase inhibitor class that was structurally derived from an earlier compound dolutegravir by scientists at Gilead Sciences; in vitro and clinical results were presented by Gilead in the summer of 2016. In 2016, bictegravir was in a Phase 3 trial as part of a single tablet regimen in combination with tenofovir alafenamide and emtricitabine for the treatment of HIV-1 infection and the combination drug bictegravir/emtricitabine/tenofovir alafenamide was approved for use in the United States in 2018.